Controlled-release PTH compound
AssigneeAscendis Pharma Bone Diseases A/S
InventorsKennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
Life of this patent
Estimating the term…
Abstract
The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.
Claims11
A parathyroid hormone (PTH) conjugate of formula:
- or a pharmaceutically acceptable salt thereof, wherein
- the unmarked dashed line indicates the attachment by an amide bond to the N-terminal nitrogen of a PTH moiety, the amino acid sequence of which consists of the sequence of SEQ ID NO:51;
- and the dashed line marked with the asterisk indicates attachment to a moiety
- wherein
- m and p are independently an integer ranging from and including 400 to 500.
A liquid pharmaceutical composition comprising a parathyroid hormone (PTH) conjugate of formula:
- or a pharmaceutically acceptable salt thereof, and a solvent, wherein
- the unmarked dashed line indicates the attachment by an amide bond to the N-terminal nitrogen of a PTH moiety, the amino acid sequence of which consists of the sequence of SEQ ID NO:51;
- and the dashed line marked with the asterisk indicates attachment to a moiety
- wherein
- m and p are independently an integer ranging from and including 400 to 500.
Dependencies are inferred from the claim text.